Thu, Jul 24, 2014, 7:51 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Curis, Inc. Message Board

donallenthompson 2 posts  |  Last Activity: May 29, 2014 10:30 AM Member since: Aug 13, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Nasal testosterone approved

    by whogo70 May 29, 2014 8:31 AM
    donallenthompson@bellsouth.net donallenthompson May 29, 2014 10:30 AM Flag

    I guess sneezing & coughing would have to be out of the question for any user. Couldn't use in cold, flu, or allergy season.

  • donallenthompson@bellsouth.net donallenthompson May 14, 2014 10:57 AM Flag

    Questions for you: How will LPCN market this product? Since they have an improved, one a day pill 18 months more or less behind & backing up the two a day pill would any BP or other smaller company want to partner the lead drug with the other so close behind? The 2 a day pill would be quite expensive to manufacture, promote, & distribute, & sell if the 1 a day is right behind it. Does any delay in marketing the oral T pill (because of the 1 a day pill in waiting) give the advantage to ATRS? I guess only a side-by-side comparison of the two stage 3 trials after completion will show if one or the other company has any other advantage over than dosing frequency. We know the ATRS shot will be a once a week, near painless injection. I think that's all we seem to know for sure. As of now, don't think either company has experienced much if any negatives in prior studies. Eventual cost of the product will be a factor. Market will probably be big enough for both. Time will tell.

CRIS
1.79+0.01(+0.56%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.